Last reviewed · How we verify

NCT06151028

An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy

Recruiting now Last updated 7 March 2024
What this trial tests

trial testing No intervention in Gynecological Malignancies in 490 participants. Currently enrolling.

Timeline
1 December 2023
Primary endpoint
31 December 2028
31 December 2033

Quick facts

Lead sponsorAnhui Provincial Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment490
Start date1 December 2023
Primary completion31 December 2028
Estimated completion31 December 2033
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Anhui Provincial Hospital

Who can join

Adults 18 to 55, female only, with Gynecological Malignancies or Menopausal Symptoms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through long-term dynamic monitoring of gynecologic malignant tumor patients undergoing early menopause after ovaries resection in our center, we explored the changes in menopausal symptoms and bone health status of this population, and studied the effects of platinum combined chemotherapy drugs on menopausal symptoms and bone loss in gynecologic malignant tumor patients. To find the optimal time point and effective regimen for MHT in gynecologic malignancies undergoing surgical menopause, and to provide guidance for osteoporosis screening and prevention strategies in women with gynecologic cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other Anhui Provincial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06151028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing